RxDoctor Payments DataLook up a doctor →

John Webb, MD

Gastroenterology · Oxford, MSNPI 1801804133

Payments from drug & device makers

$11,064in general payments, 2019–2025

Across 625 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$903
  • Sanofi$787
  • Gilead$569
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$10,73497%
  • Education$3143%
  • Gifts$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,064 in reported general payments places this provider in the 75th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi

Medicare billing

Part B allowed, 2024
$250,722
Medicare patients
852
Services billed
5,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab18$473,766
CreonLipase/Protease/Amylase31$79,425
XifaxanRifaximin15$47,941
LinzessLinaclotide36$21,523
TrulancePlecanatide23$17,866
Dexlansoprazole DrDexlansoprazole98$17,130
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates247$16,309
Mesalamine37$11,180
Pantoprazole Sodium428$3,293
Dicyclomine Hcl166$2,369
Famotidine313$2,321
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,018
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl82$1,444
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl85$1,310
CholestyramineCholestyramine (With Sugar)20$878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,086$473,76618 claims
AbbVieCreon, Linzess$1,790$100,94867 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$903$65,80738 claims
Ferring Pharmaceuticals Inc.Clenpiq$176$2,01812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 127 gastroenterology providers in Mississippi.

Other gastroenterology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →